Spot on a EDITH use case: The innovative EPFL biosensing platform
According to the World Health Organisation (WHO), cardiovascular diseases (CVDs) claim the lives of 17.9 million people every year, making them the leading cause of death worldwide. This urgency has led to a growing interest in continuous on-site monitoring of specific biomarkers that pave the way for early diagnosis and more effective treatment and follow-up.
In response, there is an urgent need to identify cardiac biomarkers early to mitigate patient outcomes and mortality based on more proactive approaches. These approaches are enabled by the use of Digital Twins (DTs). EDITH partner EPFL is developing an innovative, wearable biosensing platform as a data generator for future human DTs, using electrical sensor technology to enable multiplexed real-time detection of key cardiovascular markers with high sensitivity and selectivity.
By analysing the interstitial fluid, the EPFL solution provides a dynamic and comprehensive overview of a patient’s cardiovascular status. The real-time data generated by the EPFL platform serves as the basis for building a dynamic DT with predictive capabilities. This facilitates rapid medical interventions and clinical decisions to achieve the best possible outcomes for the patient while reducing medical errors.
Some of the results will be presented at the upcoming 1st International Symposium on Digital Twins in 2024, organised by the European Innovation Council (EIC) proactive projects Digipredict, Optomics and Neurotwin, with the participation of the EDITH coordinator and its partners.